Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axitinib and Pembrolizumab in Advanced ASPS and STS
NCT02636725Phase 2Completed
- Start
- Apr 2016
- Primary completion
- May 2018
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of axitinib and pembrolizumab in alveolar soft part sarcoma (ASPS) and soft tissue sarcoma (STS) (2 arms). Primary endpoint: Progression-Free Survival at 3 months. Started Apr 2016; status: completed.
02
Drugs
axitinibpembrolizumab
03
Conditions
alveolar soft part sarcoma (ASPS)soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT02636725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02636725.